Make predictions with SezgiX. Sign up today.
Loading…
This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants approval of intismeran autogene for any indication by December 31, 2027, 11:59 PM ET. Otherwise, this market will resolve to "No". Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program. Differences in neoantigen composition between patients will not affect resolution. Changes to the product's formulation will not a
Platform fee: 2%. Click an option to make a prediction.
Select an option above
This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants approval of intismeran autogene for any indication by December 31, 2027, 11:59 PM ET. Otherwise, this market will resolve to "No". Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program. Differences in neoantigen composition between patients will not affect resolution. Changes to the product's formulation will not affect resolution, provided the FDA approves the product described above. Approval as part of a combination regimen will qualify. Approval for a narrower population than the one studied in INTerpath-00
Prices reflect the market's implied probability of each outcome and update as people trade. Settlement is in USDC with a transparent 2% platform fee shown before confirmation. Predictions carry risk — never stake more than you can afford to lose.
What SezgiX is, how its short-duration crypto markets work, why event markets resolve against primary sources, and how a single USDC balance covers crypto, politics and sport.
95% of Polymarket users lose money long-term. The 5% who profit follow systematic strategies. This guide reveals the 10 professional methods used by profitable traders — backed by data, not guesswork.
Kalshi and Polymarket are the two giants of prediction markets in 2026. One is CFTC-regulated and US-only; the other is global, onchain, and Polygon-based. Which is right for you? This deep comparison covers every dimension.